The pharmaceutical supply chain is complex, costly, and burdened by intermediaries that drive up prices while obscuring transparency. Rising drug costs and opaque pricing demand a new approach. This session explores a direct-to-consumer, direct-to-employer pharmaceutical model designed to eliminate middlemen, increase transparency, and align incentives around patient access and employer value.